Ascension Medical Biomedical Technology Co., Ltd. (AM BIOTECH), a company specializing in induced exosome research domestically, held a press conference on January 18 to unveil its exclusive patented technology and the new generation ExoGiov and LAEXO exosome skincare products. The event featured Dr. Chung-Hsiun Wu, former Chairman of the Taiwan Bio Industry Organization, and renowned dermatologist Dr. Chian-Yaw Hwang, Director of the Yawen Dermatology Clinic, along with Dr. Ju-sheng Shieh, Chairman of AM BIOTECH. Together, they discussed the differences and advantages of AM BIOTECH’s bio-pulse induced exosomes compared to ordinary exosomes in both domestic and international markets, covering industry trends, technological innovations, and legal and regulatory aspects. This redefined the market advantages and core competitiveness of bio-pulse induced exosomes.
In his opening speech, Dr. Chung-Hsiun Wu emphasized the importance of exosomes in the future of regenerative medicine and praised AM BIOTECH as an industry pioneer. He congratulated the company on obtaining patents in Taiwan and China and anticipated further success in international markets.
During the conference, Dr. Ju-sheng Shieh, Chairman of AM Biotech, presented the strategic layout of the “bio-pulse induced exosome Technology Platform.” The company has developed over a hundred types of exosomes for regenerative medicine applications, all verified for initial efficacy through next-generation gene sequencing (NGS), quantitative polymerase chain reaction (qPCR), and cell viability tests. Collaborations with domestic teaching hospitals and institutions, including the Tri-Service General Hospital/National Defense Medical Center Taiwan, are currently underway. These collaborations involve animal testing, gearing up for upcoming clinical trials focused on regenerative materials and new drugs. With the continuous acquisition of international patents, AM BIOTECH’s Technology is well-positioned for international market expansion and has already initiated discussions for collaborations in overseas markets.
In addition to the pharmaceutical development plan, Chairman Hsieh also highlighted the skincare product “ExoGiov,” scheduled for launch in 2023. Utilizing non-human source interstitial stem cells, it complies with international cosmetic INCI standards, making it a legally compliant cosmetic extracellular vesicle ingredient for the international market. With unique functionality induction and purification technology, ExoGiov has garnered recognition from domestic dermatologists. Major competitors in the international market, particularly South Korea, are closely monitoring the developments. The year 2024 is anticipated to be a remarkable year for AM Biotech in the international market.
Dr. Chian-Yaw Hwang, a well-known dermatologist in Taiwan, shared insights on evaluating and selecting exosomes for cosmetic skincare products during the conference. Dr. Hwang emphasized the importance of safety and legality in the evaluation process. While Taiwan’s Ministry of Health and Welfare is in the process of amending regulations to prohibit the use of human-derived cells, tissues, and their derivatives in cosmetics, international restrictions on human-sourced exosomes remain in place. Until regulatory amendments are enacted, the use of non-human source exosomes and compliance with international cosmetic INCI standards are essential for skincare product applications. Dr. Hwang elaborated on the positive effects of exosomes in various skincare applications, including skin repair, scar reduction, and hair loss prevention.
Dr. Hwang further explained that AM Biotech’s bio-pulse induced exosomes, developed through exclusive patented technology, demonstrate significantly superior effects in promoting collagen, elastin, fibroblast proliferation, and hair follicle growth compared to ordinary exosomes. The efficacy has been published in international journals. Dr. Hwang highlighted the unique advantages of ExoGiov, such as the production of exosomes with a particle count 1,900 times higher and purity reaching 99.99%, both achieved through the company’s proprietary process technology, enabling storage at room temperature. This breakthrough significantly enhances the application of extracellular vesicles in skincare products.
In conclusion, AM BIOTECH announced a collaboration with Emosoxe Biotech International L.L.C. to develop the new generation LAEXO series of bio-pulsed skincare products, aiming for an international brand presence with upgraded exosome concentration and formula design.
